Research Article
Utilization of Boron Compounds for the Modification of Suberoyl Anilide Hydroxamic Acid as Inhibitor of Histone Deacetylase Class II Homo sapiens
Table 7
Ligand bioavailability.
| Ligand | Egan’s rule | Veber’s rule | Bioavability | % (Oral) > 30% | % (Oral) > 70% |
| Nova2 (9058064-6) | Good | Low | 0.03 | 0.01 | Nova2 (95752-88-8) | Good | Good | 0.85 | 0.48 | Nova2 (88765-82-6) | Good | Good | 0.85 | 0.27 | Nova2 (Unique10) | Good | Good | 0.76 | 0.27 | Nova2 (16876-27-0) | Good | Good | 0.85 | 0.48 | Nova2 (513246-99-6) | Good | Good | 0.76 | 0.27 | Nova2 (Unique80) | Good | Good | 0.76 | 0.23 | Nova2 (279262-23-6) | Good | Good | 0.59 | 0.27 |
|
|